[1] Sung H, Ferlay J, Siegel RL, et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.   doi: 10.3322/caac.21660
[2] Cao W, Chen HD, Yu YW, et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.   doi: 10.1097/CM9.0000000000001474
[3] Spolverato G, Ejaz A, Kim Y, et al.  Prognostic performance of different lymph node staging systems after curative intent resection for gastric adenocarcinoma[J]. Ann Surg, 2015, 262(6): 991-998.   doi: 10.1097/SLA.0000000000001040
[4] Sun ZP, Jiang YM, Chen CL, et al.  Radiomics signature based on computed tomography images for the preoperative prediction of lymph node metastasis at individual stations in gastric cancer: a multicenter study[J]. Radiother Oncol, 2021, 165: 179-190.   doi: 10.1016/j.radonc.2021.11.003
[5] Smyth E, Schöder H, Strong VE, et al.  A prospective evaluation of the utility of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer[J]. Cancer, 2012, 118(22): 5481-5488.   doi: 10.1002/cncr.27550
[6] Lee CM, Cho JM, Jang YJ, et al.  Should lymph node micrometastasis be considered in node staging for gastric cancer?: The significance of lymph node micrometastasis in gastric cancer[J]. Ann Surg Oncol, 2015, 22(3): 765-771.   doi: 10.1245/s10434-014-4073-z
[7]

Mpallas KD, Lagopoulos VI, Kamparoudis AG. Prognostic significance of solitary lymphnode metastasis and micrometastasis in gastric cancer[J/OL]. Front Surg, 2018, 5: 63[2023-03-02]. https://www.frontiersin.org/articles/10.3389/fsurg.2018.00063/full. DOI: 10.3389/fsurg.2018.00063.
[8] Ma DY, Zhang Y, Shao XL, et al.  PET/CT for predicting occult lymph node metastasis in gastric cancer[J]. Curr Oncol, 2022, 29(9): 6523-6539.   doi: 10.3390/curroncol29090513
[9] Liu GB, Yin HY, Cheng X, et al.  Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes[J]. Clin Exp Med, 2021, 21(1): 129-138.   doi: 10.1007/s10238-020-00659-8
[10] Kim YI, Kim YJ, Paeng JC, et al.  Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma[J]. Eur J Nucl Med Mol Imaging, 2017, 44(12): 1995-2003.   doi: 10.1007/s00259-017-3755-8
[11] Kim SJ, Pak K, Chang S.  Determination of regional lymph node status using 18F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity[J]. Br J Radiol, 2016, 89(1058): 20150673-.   doi: 10.1259/bjr.20150673
[12] Ouyang ML, Xia HW, Xu MM, et al.  Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT[J]. Ann Nucl Med, 2019, 33(9): 671-680.   doi: 10.1007/s12149-019-01375-4
[13] Chung HH, Kang SY, Ha S, et al.  Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer[J]. J Gynecol Oncol, 2016, 27(2): e15-.   doi: 10.3802/jgo.2016.27.e15
[14] Kim TH, Yoon JK, Kang DK, et al.  Correlation between F-18 fluorodeoxyglucose positron emission tomography metabolic parameters and dynamic contrast-enhanced MRI-derived perfusion data in patients with invasive ductal breast carcinoma[J]. Ann Surg Oncol, 2015, 22(12): 3866-3872.   doi: 10.1245/s10434-015-4526-z
[15] Pinho DF, King B, Xi Y, et al.  Value of intratumoral metabolic heterogeneity and quantitative 18F-FDG PET/CT parameters in predicting prognosis for patients with cervical cancer[J]. AJR Am J Roentgenol, 2020, 214(4): 908-916.   doi: 10.2214/AJR.19.21604
[16] Tixier F, Hatt M, Valla C, et al.  Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer[J]. J Nucl Med, 2014, 55(8): 1235-1241.   doi: 10.2967/jnumed.113.133389
[17] Bosch KD, Chicklore S, Cook GJ, et al.  Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment[J]. Eur J Nucl Med Mol Imaging, 2020, 47(4): 759-767.   doi: 10.1007/s00259-019-04429-x
[18] Kawanaka Y, Kitajima K, Fukushima K, et al.  Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT[J]. Eur J Radiol, 2016, 85(5): 989-995.   doi: 10.1016/j.ejrad.2016.03.003
[19] Choi JY, Shim KN, Kim SE, et al.  The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma[J]. Korean J Gastroenterol, 2014, 64(6): 340-347.   doi: 10.4166/kjg.2014.64.6.340
[20]

Na SJ, O JH, Park JM, et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with stage Ⅲ gastric cancer[J/OL]. Oncotarget, 2016, 7(39): 63968−63980[2023-03-02]. https://www.oncotarget.com/article/11574/text/. DOI: 10.18632/oncotarget.11574.
[21]

Yamada K, Urakawa N, Kanaji S, et al. Preoperative prediction of the pathological stage of advanced gastric cancer by 18F-fluoro-2-deoxyglucose positron emission tomography[J/OL]. Sci Rep, 2022, 12(1): 11370[2023-03-02]. https://www.nature.com/articles/s41598-022-14965-6. DOI: 10.1038/s41598-022-14965-6.
[22] 张在炬, 陈亚明, 丁正强, 等.  18F-FDG PET/CT代谢参数与胃癌临床病理特征的相关性分析[J]. 临床和实验医学杂志, 2021, 20(13): 1450-1454.   doi: 10.3969/j.issn.1671-4695.2021.13.030
Zhang ZJ, Chen YM, Ding ZQ, et al.  Correlation between 18F-FDG PET/CT metabolic parameters and clinicopathological features of gastric cancer[J]. J Clin Exp Med, 2021, 20(13): 1450-1454.   doi: 10.3969/j.issn.1671-4695.2021.13.030
[23] Oh HH, Lee SE, Choi IS, et al.  The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer[J]. J Surg Oncol, 2011, 104(5): 530-533.   doi: 10.1002/jso.21985
[24] Boellaard R, Delgado-Bolton R, Oyen WJG, et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354.   doi: 10.1007/s00259-014-2961-x
[25] 朱娅华, 邓玮玮, 范敏, 等.  18F-FDG PET/CT显像在胃癌分期及治疗方案制定中的应用价值[J]. 国际放射医学核医学杂志, 2018, 42(1): 15-20.   doi: 10.3760/cma.j.issn.1673-4114.2018.01.003
Zhu YH, Deng WW, Fan M, et al.  Value of 18F-FDG PET/CT imaging on the staging of gastric carcinoma and its influence on therapeutic schedule formulation[J]. Int J Rad Med Nucl Med, 2018, 42(1): 15-20.   doi: 10.3760/cma.j.issn.1673-4114.2018.01.003
[26] Perlaza P, Ortín J, Pagès M, et al.  Should 18F-FDG PET/CT Be routinely performed in the clinical staging of locally advanced gastric adenocarcinoma?[J]. Clin Nucl Med, 2018, 43(6): 402-410.   doi: 10.1097/RLU.0000000000002028
[27] 周锦, 张漫雪, 胡秀芝, 等.  原发胃癌18F-FDG PET/CT代谢参数与临床病理特征的相关性[J]. 中国医学影像技术, 2019, 35(1): 95-99.   doi: 10.13929/j.1003-3289.201806068
Zhou J, Zhang MX, Hu XZ, et al.  Correlation of 18F-FDG PET/CT metabolic parameters and clinicopathological factors of primary gastric cancer[J]. Chin J Med Imaging Technol, 2019, 35(1): 95-99.   doi: 10.13929/j.1003-3289.201806068
[28]

Xue XQ, Yu WJ, Shao XL, et al. Incremental value of PET primary lesion-based radiomics signature to conventional metabolic parameters and traditional risk factors for preoperative prediction of lymph node metastases in gastric cancer[J/OL]. Abdom Radiol (NY), 2023, 48(2): 510−518[2023-03-02]. https://link.springer.com/article/10.1007/s00261-022-03738-4. DOI: 10.1007/s00261-022-03738-4.
[29] 王建林, 丁晓芳, 马晚俊, 等.  18F-FDG PET/CT代谢参数及代谢异质性与胃癌临床病理特征的相关性[J]. 中国临床医学影像杂志, 2022, 33(6): 414-418,429.   doi: 10.12117/jccmi.2022.06.008
Wang JL, Ding XF, Ma WJ, et, al.  Correlation of 18F-FDG PET/CT metabolic parameters and metabolic heterogeneity with clinicopathological features of gastric cancer[J]. J China Clin Med Imaging, 2022, 33(6): 414-418,429.   doi: 10.12117/jccmi.2022.06.008
[30]

Kobayashi S, Ogura M, Suzawa N, et al. 18F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis[J/OL]. BMC Med Imaging, 2016, 16(1): 58[2023-03-02]. https://bmcmedimaging.biomedcentral.com/articles/10.1186/s12880-016-0161-9. DOI: 10.1186/s12880-016-0161-9.